CD79A work as a potential target for the prognosis of patients with OSCC: analysis of immune cell infiltration in oral squamous cell carcinoma based on the CIBERSORTx deconvolution algorithm.
CD79A
Infiltration abundance
Oral squamous cell carcinoma
Target prediction
Tumor microenvironment
Tumor-infiltrating immune cells
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
21 06 2023
21 06 2023
Historique:
received:
18
10
2022
accepted:
04
04
2023
medline:
23
6
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
To analyze the abundance of infiltrating tumor immune cells in patients with oral squamous cell carcinoma (OSCC) and to search for potential targets that can predict patient prognosis. A total of 400 samples from 210 patients with OSCC were collected using The Cancer Genome Atlas (TCGA) database. CIBERSORTx was used to evaluate the infiltration abundance of tumor immune cells. Potential target genes were searched to predict patient prognosis through case grouping, differential analysis, and enrichment analysis. Surgical excisional tissue sections of patients with oral squamous cell carcinoma admitted to the Department of Oral and Maxillofacial Surgery, Second Affiliated Hospital of Shantou University Medical College, from 2015 to 2018 were collected and followed up. The CIBERSORTx deconvolution algorithm was used to analyze the infiltration abundance of immune cells in the samples. Cases with a high infiltration abundance of naive and memory B lymphocytes improved the prognosis of OSCC patients. The prognosis of patients with low CD79A expression was significantly better than that of patients with high CD79A expression. CD79A can predict the infiltration abundance of B lymphocytes in the tumor microenvironment of patients with OSCC. CD79A is a potential target for predicting the prognosis of patients with OSCC. This study provides novel ideas for the treatment of OSCC and for predicting patient prognosis.
Identifiants
pubmed: 37344840
doi: 10.1186/s12903-023-02936-w
pii: 10.1186/s12903-023-02936-w
pmc: PMC10286476
doi:
Substances chimiques
CD79A protein, human
0
CD79 Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
411Informations de copyright
© 2023. The Author(s).
Références
Mol Ther Nucleic Acids. 2020 Aug 29;22:298-309
pubmed: 33230435
Oral Oncol. 2019 Mar;90:115-121
pubmed: 30846169
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
PLoS One. 2013 Oct 16;8(10):e76115
pubmed: 24146823
Nature. 2021 Sep;597(7875):279-284
pubmed: 34471285
F1000Res. 2016 Jun 20;5:1438
pubmed: 27508061
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cancer Biol Med. 2020 Feb 15;17(1):20-31
pubmed: 32296574
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Exp Hematop. 2020 Sep 25;60(3):78-86
pubmed: 32641598
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Front Med (Lausanne). 2020 Sep 17;7:451
pubmed: 33043022
Front Genet. 2022 Aug 30;13:983672
pubmed: 36110217
Front Oncol. 2021 Jun 10;11:686792
pubmed: 34178680
Commun Biol. 2021 Jan 15;4(1):73
pubmed: 33452446
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Nature. 2013 Sep 19;501(7467):338-45
pubmed: 24048066
Front Immunol. 2022 Oct 03;13:1018685
pubmed: 36263048
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Curr Oncol Rep. 2020 Jun 29;22(8):81
pubmed: 32602047
Front Genet. 2022 Aug 26;13:984273
pubmed: 36092898
Oral Oncol. 2013 Dec;49(12):1089-96
pubmed: 24126223
Mayo Clin Proc. 2008 Apr;83(4):489-501
pubmed: 18380996
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Adv Sci (Weinh). 2022 Nov 16;:e2202437
pubmed: 36382555
BMC Clin Pathol. 2014 Aug 23;14:38
pubmed: 25177210
Oral Oncol. 2009 Apr-May;45(4-5):440-6
pubmed: 18674958
Blood Adv. 2021 Nov 23;5(22):4535-4548
pubmed: 34614508
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Nat Rev Cancer. 2022 Jul;22(7):414-430
pubmed: 35393541
J Immunol. 2019 Jan 1;202(1):278-291
pubmed: 30530592
Immunotherapy. 2021 Jun;13(9):723-726
pubmed: 33910385